Latest & greatest articles for knee replacement

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on knee replacement or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on knee replacement and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for knee replacement

81. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. (Abstract)

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Low-molecular-weight heparins such as enoxaparin are preferred for prevention of venous thromboembolism after major joint replacement. Apixaban, an orally active factor Xa inhibitor, might be as effective, have lower bleeding risk, and be easier to use than is enoxaparin. We assessed efficacy and safety of these drugs after elective total knee replacement.In ADVANCE-2 (...) , a multicentre, randomised, double-blind phase 3 study, patients undergoing elective unilateral or bilateral total knee replacement were randomly allocated through an interactive central telephone system to receive oral apixaban 2.5 mg twice daily (n=1528) or subcutaneous enoxaparin 40 mg once daily (1529). The randomisation schedule was generated by the Bristol-Myers Squibb randomisation centre and stratified by study site and by unilateral or bilateral surgery with a block size of four. Investigators

2010 Lancet Controlled trial quality: predicted high

82. Is a tourniquet beneficial in total knee replacement surgery? A meta-analysis and systematic review

Is a tourniquet beneficial in total knee replacement surgery? A meta-analysis and systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

83. Is longer waiting time for total knee replacement associated with health outcomes and medication costs? Randomized clinical trial

Is longer waiting time for total knee replacement associated with health outcomes and medication costs? Randomized clinical trial Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 NHS Economic Evaluation Database.

84. Clinical and radiological outcomes of fixed- versus mobile-bearing total knee replacement: a meta-analysis

Clinical and radiological outcomes of fixed- versus mobile-bearing total knee replacement: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

85. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement Full Text available with Trip Pro

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged (...) over 75 years or with moderate renal impairment undergoing total knee or hip replacement Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Noack H, Robinson PA, Dolan G, Brenkel IJ Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study

2010 NHS Economic Evaluation Database.

86. Postoperative analgesia and early rehabilitation after total knee replacement: a comparison of continuous low-dose intravenous ketamine versus nefopam (Abstract)

Postoperative analgesia and early rehabilitation after total knee replacement: a comparison of continuous low-dose intravenous ketamine versus nefopam The effects of nefopam and ketamine on pain control and rehabilitation after total knee replacement were compared in a prospective, double blinded study. Seventy-five patients were randomly assigned to receive a 0.2mg kg(-1) bolus of nefopam or ketamine, followed by a 120microg kg(-1) h(-1) continuous infusion until the end of surgery (...) , respectively, p=0.01). Ketamine produces opioid-sparing, decreases pain intensity, and improves mobilization after total knee replacement. Nefopam achieves less significant results in that circumstances.

2009 EvidenceUpdates Controlled trial quality: uncertain

87. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement Full Text available with Trip Pro

Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement A once-daily dose of rivaroxaban 10 mg, an oral, direct Factor Xa inhibitor, was compared with enoxaparin 40 mg subcutaneously once daily for prevention of venous thromboembolism in three studies of patients undergoing elective hip and knee replacement (RECORD programme). A pooled analysis of data from these studies (n = 9581) showed that rivaroxaban was more effective than

2009 EvidenceUpdates Controlled trial quality: uncertain

88. A specific inpatient aquatic physiotherapy program improves strength after total hip or knee replacement surgery: a randomized controlled trial (Abstract)

A specific inpatient aquatic physiotherapy program improves strength after total hip or knee replacement surgery: a randomized controlled trial To evaluate the effect of inpatient aquatic physiotherapy in addition to usual ward physiotherapy on the recovery of strength, function, and gait speed after total hip or knee replacement surgery.Pragmatic randomized controlled trial with blinded 6-month follow-up.Acute-care private hospital.People (n=65) undergoing primary hip or knee arthroplasty (...) at any time point in the trial, but relative differences favored the aquatic physiotherapy intervention at day 14. No adverse events occurred with early aquatic intervention.A specific inpatient aquatic physiotherapy program has a positive effect on early recovery of hip strength after joint replacement surgery. Further studies are required to confirm these findings. Our research indicates that aquatic physiotherapy can be safely considered in this early postoperative phase.

2009 EvidenceUpdates Controlled trial quality: predicted high

89. Functional outcome and range of motion of high-flexion posterior cruciate-retaining and high-flexion posterior cruciate-substituting total knee prostheses. A prospective, randomized study (Abstract)

Functional outcome and range of motion of high-flexion posterior cruciate-retaining and high-flexion posterior cruciate-substituting total knee prostheses. A prospective, randomized study Although the design features of the high-flexion posterior cruciate-retaining and high-flexion posterior cruciate-substituting total knee prostheses reportedly improve the range of knee motion, a clinical comparison of both systems with regard to range of motion has not been reported, to our knowledge (...) . The purpose of the present study was to compare the range of motion and functional outcome in knees receiving either a high-flexion posterior cruciate-retaining or a high-flexion posterior cruciate-substituting total knee prosthesis.Two hundred and fifty patients (mean age, 71.6 years) received a high-flexion posterior cruciate-retaining total knee prosthesis in one knee and a high-flexion posterior cruciate-substituting total knee prosthesis in the contralateral knee. Ten patients were men, and 240 were

2009 EvidenceUpdates Controlled trial quality: uncertain

90. Land-based versus water-based rehabilitation following total knee replacement: A randomized, single-blind trial (Abstract)

Land-based versus water-based rehabilitation following total knee replacement: A randomized, single-blind trial To compare outcomes between land-based and water-based exercise programs delivered in the early subacute phase up to 6 months after total knee replacement (TKR).Two weeks after surgery (baseline), 102 patients were randomized to participate in either land-based (n = 49) or water-based (n = 53) exercise classes. Treatment parameters were guided by current clinical practice protocols (...) . Therefore, each study arm involved 1-hour sessions twice a week for 6 weeks, with patient-determined exercise intensity. Session attendance was recorded. Outcomes were measured at baseline and at 8 and 26 weeks postsurgery. Outcomes included distance on the 6-Minute Walk test, stair climbing power (SCP), the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index (n = 85 English-proficient patients), visual analog scale for joint pain, passive knee range of motion, and knee edema

2009 EvidenceUpdates Controlled trial quality: uncertain

91. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170)

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults (TA170) Overview | Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults | Guidance | NICE Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults Technology appraisal guidance [TA170] Published date: 22 April 2009 Share Guidance on rivaroxaban (Xarelto) for preventing venous (...) thromboembolism after total hip or total knee replacement in adults. Guidance development process Is this guidance up to date? . We found nothing new that affects the recommendations in this guidance. Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations. Your responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health

2009 National Institute for Health and Clinical Excellence - Technology Appraisals

92. Prostheses for primary total knee replacement in Italy

Prostheses for primary total knee replacement in Italy Prostheses for primary total knee replacement in Italy Prostheses for primary total knee replacement in Italy Cerbo M, Fella D, Jefferson T, Migliore A, Paone S, Perrini MR, Velardi L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Cerbo M, Fella D, Jefferson T, Migliore A, Paone S (...) , Perrini MR, Velardi L. Prostheses for primary total knee replacement in Italy. Rome: Agenzia nazionale per i servizi sanitari regionali. 2009 Authors' objectives We aimed to identify the TKR prostheses currently used in Italy, to retrieve evidence of performance for all the models identified from clinical studies and arthroplasty registers, and to construct a cost-effectiveness model to support the choice for healthcare payers. Authors' conclusions Despite the limitations and constraints of our study

2009 Health Technology Assessment (HTA) Database.

93. Rivaroxaban and dabigatran for thromboprophylaxis in patients undergoing total hip or knee replacement

Rivaroxaban and dabigatran for thromboprophylaxis in patients undergoing total hip or knee replacement Home - Monash Health Find a Location Latest news Victorian Minister for Health Jenny Mikakos MP meets a patient and researcher leading the world-first safety trial examining stem cells as therapy for acute stroke. Your health Heat kills more people than any natural disaster. Be prepared and survive the heat this summer. Our children’s hospital Monash Children’s Hospital is one of Australia’s

2009 Monash Health Evidence Reviews

94. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. (Abstract)

Apixaban or enoxaparin for thromboprophylaxis after knee replacement. The optimal strategy for thromboprophylaxis after major joint replacement has not been established. Low-molecular-weight heparins such as enoxaparin predominantly target factor Xa but to some extent also inhibit thrombin. Apixaban, a specific factor Xa inhibitor, may provide effective thromboprophylaxis with a low risk of bleeding and improved ease of use.In a double-blind, double-dummy study, we randomly assigned patients (...) undergoing total knee replacement to receive 2.5 mg of apixaban orally twice daily or 30 mg of enoxaparin subcutaneously every 12 hours. Both medications were started 12 to 24 hours after surgery and continued for 10 to 14 days. Bilateral venography was then performed. The primary efficacy outcome was a composite of asymptomatic and symptomatic deep-vein thrombosis, nonfatal pulmonary embolism, and death from any cause during treatment. Patients were followed for 60 days after anticoagulation therapy

2009 NEJM Controlled trial quality: predicted high

95. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults

Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 170. 2009 Authors' conclusions Rivaroxaban, within its marketing authorisation, is recommended as an option for the prevention of venous thromboembolism in adults having elective total hip

2009 Health Technology Assessment (HTA) Database.

96. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery Wolowacz S E, Roskell N S, Maciver F, Beard S M, Robinson P A, Plumb J M, Dolan G, Brenkel I J (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of oral dabigatran etexilate (DE) versus subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement

2009 NHS Economic Evaluation Database.

97. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting

A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium (...) as thromboprophylaxis after total hip and total knee replacement in the Irish healthcare setting McCullagh L, Tilson L, Walsh C, Barry M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of rivaroxaban

2009 NHS Economic Evaluation Database.

98. Pre-operative injections of epoetin-{alpha} versus post-operative retransfusion of autologous shed blood in total hip and knee replacement Full Text available with Trip Pro

Pre-operative injections of epoetin-{alpha} versus post-operative retransfusion of autologous shed blood in total hip and knee replacement This prospective randomised clinical trial evaluated the effect of alternatives for allogeneic blood transfusions after total hip replacement and total knee replacement in patients with pre-operative haemoglobin levels between 10.0 g/dl and 13.0 g/dl. A total of 100 patients were randomly allocated to the Eprex (pre-operative injections of epoetin (...) ) and 30% (nine of 30 patients) (p = 0.047) respectively, whereas in total knee replacement, the percentages were 0% (0 of 20 patients) and 25% (five of 20 patients) respectively (p = 0.042). Pre-operative epoetin injections are more effective but more costly in reducing the need for allogeneic blood transfusions in mildly anaemic patients than post-operative retransfusion of autologous blood.

2008 EvidenceUpdates Controlled trial quality: uncertain

99. Computer-assisted and conventional total knee replacement Full Text available with Trip Pro

Computer-assisted and conventional total knee replacement After obtaining informed consent, 80 patients were randomised to undergo a navigated or conventional total knee replacement. All received a cemented, unconstrained, cruciate-retaining implant with a rotating platform. Full-length standing and lateral radiographs and CT scans of the hip, knee and ankle joint were carried out five to seven days after operation. No notable differences were found between computer-assisted navigation

2008 EvidenceUpdates Controlled trial quality: uncertain

100. After partial knee replacement, patients can kneel, but they need to be taught to do so: a single-blind randomized controlled trial Full Text available with Trip Pro

After partial knee replacement, patients can kneel, but they need to be taught to do so: a single-blind randomized controlled trial Kneeling is an important functional activity frequently not performed after knee replacement, thus affecting a patient's ability to carry out basic daily tasks. Despite no clinical reason preventing kneeling, many patients fail to resume this activity. The purpose of this study was to determine whether a single physical therapy intervention would improve patient (...) -reported kneeling ability following partial knee replacement (PKR).Sixty adults with medial compartment osteoarthritis, suitable for a PKR, participated.This was a single-blind, prospective randomized controlled trial. Six weeks after PKR, participants randomly received either kneeling advice and education or routine care where no specific kneeling advice was given. Reassessment was at 1 year postoperatively. The primary outcome measure was patient-reported kneeling ability, as assessed by question 7

2008 EvidenceUpdates Controlled trial quality: uncertain